µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y502 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¸ÞÆ¿»êƾ Methylxanthines, NEC causing adverse effects in therapeutic use
Y502 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ä«ÆäÀÎ Caffeine causing adverse effects in therapeutic use
Y508 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ Other central nervous system stimulants causing adverse effects in therapeutic use
Y509 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ Central nervous system stimulant, unspecified causing adverse effects in therapeutic use
Y51 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÀÚÀ²½Å°æ°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ Drugs primarily affecting the autonomic nervous system causing adverse effects in therapeutic use
Y510 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Äݸ°¿¡½ºÆ®·¹À̽ºÁ¦ Anticholinesterase agents causing adverse effects in therapeutic use
Y511 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ºÎ±³°¨½Å°æÀÛ¿ëÁ¦[Äݸ°Á¦] Other parasympathomimetics[cholinergics] causing adverse effects in therapeutic use
Y512 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ½Å°æÀýÂ÷´ÜÁ¦ Ganglionic blocking drugs, NEC causing adverse effects in therapeutic use
Y513 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ ºÎ±³°¨½Å°æÂ÷´ÜÁ¦ [Ç×Äݸ°Á¦ ¹× Ç×¹«½ºÄ«¸°Á¦] ¹× ¿¬Ãà¾ðÁ¦Á¦ Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, NEC causing adverse effects in therapeutic use
Y513 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÆÄÆÄº£¸° Papaverine causing adverse effects in therapeutic use
Y514 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¿ì¼¼¼º º£¾ËÆÄ-¾Æµå·¹³ª¸° ¼ö¿ëü ÀÛ¿ëÁ¦ Predominantly ¥á-adrenoreceptor agonists, NEC causing adverse effects in therapeutic use
Y514 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸¶Å¸¶ó¹Ì³î Metaraminol causing adverse effects in therapeutic use
Y515 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¿ì¼¼¼º º£Å¸-¾Æµå·¹³ª¸° ¼ö¿ëü ÀÛ¿ëÁ¦ Predominantly ¥â-adrenoreceptor agonists, NEC causing adverse effects in therapeutic use
Y516 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¾ËÆÄ-¾Æµå·¹³ª¸°¼ö¿ëü ±æÇ×Á¦ ¥á-adrenoreceptor antagonists,NEC causing adverse effects in therapeutic use
Y517 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº º£Å¸-¾Æµå·¹³¯¸°¼ö¿ëü ±æÇ×Á¦ ¥â-adrenoreceptor antagonists, NEC causing adverse effects in therapeutic use
Y518 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃß¼º ÀÛ¿ë ¹× ¾Æµå·¹³¯¸°-´º·Ð-Â÷´ÜÁ¦ Centrally acting and adrenergic-neuron-blocking agents, NEC causing adverse effects in therapeutic use
Y519 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷ÀûÀ¸·Î ÀÚÀ²½Å°æ°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ Other and unspecified drugs primarily affecting the autonomic nervous system causing adverse effects in therapeutic use
Y519 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ËÆÄ ¹× º£Å¸ ¾Æµå·¹³ª¸° ¼ö¿ëü ¸ðµÎ¸¦ ÀÚ±ØÇÏ´Â ¾àÁ¦ Drugs stimulating both ¥á- and ¥â-adrenoreceptors causing adverse effects in therapeutic use
Y52 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ½ÉÇ÷°ü°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use
Y520 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½ÉÀåÀÚ±Ø ¹è´çü ¹× À¯»çÀÛ¿ë ¾à¹° Cardiac-stimulant glycosides and drugs of similar action causing adverse effects in therapeutic use
1911  1912  1913  [1914] 1915  1916  1917  1918  1919  1920